肺癌筛检市场规模、份额和成长分析（按癌症类型、诊断方法、最终用户和地区划分）—2026-2033年产业预测

2024 年全球肺癌筛检市场规模为 38.2 亿美元，预计将从 2025 年的 41.7 亿美元成长到 2033 年的 83.6 亿美元，预计在预测期（2026-2033 年）内将以 9.1% 的复合年增长率。

受筛检技术进步和全球吸烟率上升的推动，全球肺癌筛检市场正经历强劲成长。由于许多人仍然每天吸烟，肺癌发病率的不断上升推动了对有效筛检方案的需求。医疗专业人员对低剂量电脑断层扫描（CT）的广泛应用进一步促进了这项需求。此外，人们对创新且经济实惠的筛检方法的认识不断提高，尤其是在开发中国家，也促进了市场扩张。主要参与者之间的合作策略，例如旨在提高公众意识的伙伴关係，也发挥着重要作用。然而，为了实现永续成长，需要透过技术创新和教育宣传活动来解决高昂的筛检成本和对辐射暴露的担忧等挑战。

推动全球肺癌筛检市场发展的因素

肺癌是全球癌症死亡的首要原因，其发生率的不断上升是推动肺癌筛检政策实施的关键因素。病例数的增加，尤其是在开发中国家，凸显了有效早期检测策略的迫切性。随着人们对筛检益处的认识不断提高，卫生系统也逐渐认识到采取积极措施在早期发现和治疗肺癌的重要性。这种对筛检的日益重视不仅旨在降低死亡率，也强调了更广泛的预防保健的重要性。

全球肺癌筛检市场面临的限制因素

全球肺癌筛检市场面临许多挑战，其中低剂量电脑断层扫描（LDCT）可能出现伪阳性结果。这些假阳性结果可能导致患者需要进行额外的检查，造成不必要的焦虑，增加医疗成本，并可能增加不必要的医疗程序带来的併发症风险。此外，过度诊断问题也日益凸显，即患者被发现存在一些不太可能构成威胁的肺结节，导致过度治疗和不必要的干预。这些因素加剧了人们对肺癌筛检的犹豫和怀疑，最终阻碍了市场成长和普及。

全球肺癌筛检市场趋势

全球肺癌筛检市场正经历显着的转变，朝着根据个别风险状况量身定制的个人化筛检方法发展。透过整合吸烟史、职业暴露和遗传易感性等因素，医疗机构正在提高筛检计画的准确性和有效性。这一趋势着重于利用风险分层演算法来识别和优先筛选高风险族群，从而优化资源分配并提高早期检出率。随着人们对肺癌的认识不断提高以及推动个人化医疗的技术进步，这种客製化策略有望在全球肺癌筛检通讯协定的变革中发挥关键作用。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 技术进步
• 监管环境
• 专利分析

全球肺癌筛检市场规模（按癌症类型和复合年增长率划分）（2026-2033 年）

• 非小细胞肺癌（NSCLC）
• 小细胞肺癌

全球肺癌筛检市场规模（按诊断方法和复合年增长率划分）（2026-2033 年）

• 低剂量螺旋电脑断层扫描
• 胸部X光片

全球肺癌筛检市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 诊断中心

全球肺癌筛检市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• General Electric Company（USA）
• Koninklijke Philips NV（Netherlands）
• Siemens Healthineers（Germany）
• Canon Medical Systems Corporation（Japan）
• FUJIFILM Holdings Corporation（Japan）
• Medtronic（USA）
• Nuance Communications, Inc.（USA）
• Eon（USA）
• Volpara Health Limited（New Zealand）
• Hitachi, Ltd.（Japan）
• Toshiba Corporation（Japan）
• Hologic, Inc.（USA）
• Agfa-Gevaert Group（Belgium）
• Carestream Health（USA）
• Mindray Medical International Limited（China）
• Esaote SpA（Italy）
• Shimadzu Corporation（Japan）
• ViewRay, Inc.（USA）

结论与建议

Global Lung Cancer Screening Market size was valued at USD 3.82 Billion in 2024 and is poised to grow from USD 4.17 Billion in 2025 to USD 8.36 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).

The global lung cancer screening market is experiencing robust growth, propelled by advancements in screening technologies and the rising rates of tobacco use worldwide. With significant numbers of individuals routinely engaging in tobacco consumption, the need for effective screening solutions has intensified due to the increasing incidence of lung cancer. The widespread adoption of low-dose computed tomography (CT) among healthcare professionals further fuels this demand. Additionally, heightened awareness of innovative and affordable screening methods, especially in developing nations, contributes to market expansion. Collaborative strategies among key players, such as partnerships aimed at increasing public awareness, also play a pivotal role. Nonetheless, challenges such as high screening costs and radiation exposure concerns must be addressed through technological advancements and educational initiatives for sustainable growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Screening Market Segments Analysis

Global Lung Cancer Screening Market is segmented by Cancer Type, Diagnosis Type, End-user and region. Based on Cancer Type, the market is segmented into Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer. Based on Diagnosis Type, the market is segmented into Low Dose Spiral CT Scan and Chest X-ray. Based on End-user, the market is segmented into Hospitals & Clinics and Diagnostic Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Screening Market

The increasing prevalence of lung cancer, a major contributor to cancer mortality globally, serves as a crucial catalyst for the implementation of lung cancer screening initiatives. The uptick in cases, especially within developing nations, highlights the urgent need for effective early detection strategies. As awareness about the benefits of screening continues to grow, healthcare systems are recognizing the importance of proactive measures to identify and tackle lung cancer at its nascent stages. This heightened focus on screening not only aims to reduce mortality rates but also emphasizes the importance of preventive healthcare on a broader scale.

Restraints in the Global Lung Cancer Screening Market

The global lung cancer screening market faces significant challenges due to the potential for false-positive results stemming from low-dose computed tomography (LDCT). These false positives can necessitate further examinations, which may induce unwarranted anxiety in patients, incur extra expenses, and raise the risk of complications associated with unnecessary medical procedures. Additionally, the issue of overdiagnosis arises when patients are identified with lung nodules that are unlikely to pose any threat, resulting in overtreatment and unwarranted interventions. These factors contribute to hesitancy and skepticism surrounding lung cancer screening, ultimately hindering market growth and adoption.

Market Trends of the Global Lung Cancer Screening Market

The Global Lung Cancer Screening market is experiencing a notable shift towards personalized screening approaches that cater to individual risk profiles. By integrating factors such as smoking history, occupational exposures, and genetic predispositions, healthcare providers are enhancing the precision and effectiveness of screening programs. This trend emphasizes the use of risk stratification algorithms to identify and prioritize high-risk populations, thereby optimizing resource allocation and improving early detection rates. As awareness of lung cancer grows and technological advancements facilitate personalized medicine, this tailored strategy is expected to play a crucial role in transforming lung cancer screening protocols worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Advancement
• Regulatory Landscape
• Patent Analysis

Global Lung Cancer Screening Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer

Global Lung Cancer Screening Market Size by Diagnosis Type & CAGR (2026-2033)

• Market Overview
• Low Dose Spiral CT Scan
• Chest X-ray

Global Lung Cancer Screening Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers

Global Lung Cancer Screening Market Size & CAGR (2026-2033)

• North America (Cancer Type, Diagnosis Type, End-user)
  • US
  • Canada
• Europe (Cancer Type, Diagnosis Type, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Diagnosis Type, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Diagnosis Type, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Diagnosis Type, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• General Electric Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuance Communications, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eon (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Volpara Health Limited (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi, Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Toshiba Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agfa-Gevaert Group (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carestream Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindray Medical International Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Esaote S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViewRay, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations